Results 1 to 10 of about 86,485 (257)

Tocilizumab for treatment of patients with severe COVID–19: A retrospective cohort study

EClinicalMedicine, 2020
Background: Tocilizumab was approved for chimeric antigen receptor T–cell therapy induced cytokine release syndrome and it may provide clinical benefit for selected COVID–19 patients. Methods: In this retrospective cohort study, we analyzed hypoxic COVID–
Fahrettin Covut, Tariq Kewan, Mohammed J Al-Jaghbeer   +2 more
exaly   +3 more sources

Optimal use of tocilizumab for severe and critical COVID-19: a systematic review and meta-analysis [version 1; peer review: 1 approved, 2 approved with reservations]

F1000Research, 2021
Background: Several studies have revealed the potential use of tocilizumab in treating COVID-19 since no therapy has yet been approved for COVID-19 pneumonia.
Cahyo Wibisono Nugroho, Satriyo Dwi Suryantoro, Yuliasih Yuliasih, Alfian Nur Rosyid, Tri Pudy Asmarawati, Lucky Andrianto, Herley Windo Setiawan, Bagus Aulia Mahdi, Choirina Windradi, Esthiningrum Dewi Agustin, Jonny Karunia Fajar   +10 more
doaj   +1 more source

Efficacious switching from subcutaneous to intravenous tocilizumab in patients with non-infectious non-anterior uveitis

Journal of Ophthalmic Inflammation and Infection, 2023
Purpose The efficacy of tocilizumab in refractory chronic noninfectious uveitis has been previously reported, but no data comparing intravenous and subcutaneous tocilizumab in uveitis are available.
Mathilde Leclercq, Paul Goupillou, Hélène Gomez, Marc Muraine, Ygal Benhamou, Nicolas Girszyn, Julie Gueudry   +6 more
doaj   +1 more source

Tocilizumab treatment in critically ill patients with COVID-19: A retrospective observational study

International Journal of Infectious Diseases, 2021
Objective: Elevated levels of pro-inflammatory cytokines are observed in severe COVID-19 infections, and cytokine storm is associated with disease severity.
Edmund Huang, Sharon Isonaka, Haoshu Yang, Erin Salce, Elisa Rosales, Stanley C. Jordan   +5 more
doaj   +1 more source

Retrospective cohort study to assess the association between treatment with tocilizumab and mortality among mechanically ventilated patients with COVID-19

BMJ Open, 2022
Objectives Assess the association between tocilizumab administration and clinical outcomes among mechanically ventilated patients with COVID-19 pneumonia.Design Retrospective cohort study.Setting Large integrated health system with 9 million members in ...
Sara Y Tartof, Lei Qian, Liyan Liu, Devin Incerti, Jacek Skarbinski, Laura B Amsden, Bradley K Ackerson, Vennis Hong, Bruce H Fireman, Vincent M Yau, Heidi Fischer, Sally F Shaw   +11 more
doaj   +1 more source

LC-MS/MS method for the quantitation of serum tocilizumab in rheumatoid arthritis patients using rapid tryptic digestion without IgG purification

Journal of Pharmaceutical Analysis, 2022
The quantitation of serum tocilizumab using liquid chromatography tandem-mass spectrometry (LC-MS/MS) method has not been widely applied in clinical settings because of its time-consuming and costly sample pretreatments.
Takashi Mochizuki, Kaito Shibata, Takafumi Naito, Kumiko Shimoyama, Noriyoshi Ogawa, Masato Maekawa, Junichi Kawakami   +6 more
doaj   +1 more source

Subcutaneous tocilizumab in the management of non-infectious uveitis in children: a brief report

Pediatric Rheumatology Online Journal, 2023
Background Tocilizumab is a humanized monoclonal antibody that acts as an IL-6 receptor antagonist. Intravenous tocilizumab is considered an option for children with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis.
Francesca Burlo, Cristina Tumminelli, Serena Pastore, Gabriele Stocco, Debora Curci, Marianna Lucafò, Alberto Tommasini, Andrea Taddio   +7 more
doaj   +1 more source

Early Tocilizumab Dosing Is Associated With Improved Survival in Critically Ill Patients Infected With Severe Acute Respiratory Syndrome Coronavirus-2

Critical Care Explorations, 2021
Objectives:. To identify the most efficacious timing for tocilizumab administration in critically ill patients infected with severe acute respiratory syndrome coronavirus-2. Design:. Observational multicenter cohort study. Setting:.
Russell M. Petrak, MD, Nicholas W. Van Hise, PharmD, Nathan C. Skorodin, PharmD, Robert M. Fliegelman, DO, Vishnu Chundi, MD, Vishal Didwania, MD, Alice Han, MD, Brian P. Harting, MD, David W. Hines, MD   +8 more
doaj   +1 more source

Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab

Open Heart, 2023
Background Tocilizumab improves myocardial salvage index (MSI) in patients with ST-elevation myocardial infarction (STEMI), but its mechanisms of action are unclear. Here, we explored how cytokines were affected by tocilizumab and their correlations with
Ola Kleveland, Rune Wiseth, Jan Kristian Damås, Pål Aukrust, Lars Gullestad, Bente Halvorsen, Einar Hopp, Kaspar Broch, T Ueland, Anne Kristine Anstensrud, Sindre Woxholt, Bjørn Bendz, Brage H Amundsen, Nils-Einar Kløw, Ingebjørg Seljeflot, Geir Øystein Andersen, Ingvild Maria Tøllefsen, Liv Ryan, Tuva B Dahl, Camilla Huse   +19 more
doaj   +1 more source

Effect of Tocilizumab in Mortality among Patients with Severe and Critical Covid-19: Experience in a Third-Level Medical Center

Revista de Investigación Clínica, 2022
Background: Trials evaluating safety and efficacy of tocilizumab in coronavirus disease 19 (COVID-19) show contradictory results. Objective: The objective of the study was to evaluate the effect of tocilizumab in hospital mortality among patients with ...
Bernardo A. Martinez-Guerra, Nereyda A. de-León-Cividanes, Karla M. Tamez-Torres, Carla M. Román-Montes, Sandra Rajme-López, Edgar Ortiz-Brizuela, Carlos A. Aguilar-Salinas, Juan Sierra-Madero, José Sifuentes-Osornio, Alfredo Ponce-de-León, María F. González-Lara   +10 more
doaj   +1 more source